Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  ArGEN-X    ARGX   NL0010832176

ARGEN-X (ARGX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

arGEN X : argenx to Present at Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2018 | 07:01am CEST

May 17, 2018

Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present at several upcoming investor conferences:

  • UBS 2018 Global Healthcare ConferenceCompany presentation on Tuesday, May 22, 2018 at 2:00 p.m. ET in New York City.
  • Jefferies 2018 Global Healthcare Conference. Company presentation on Wednesday, June 6, 2018 at 1:30 p.m. ET in New York City.
  • JMP Securities Life Sciences ConferencePanel discussion on Wednesday, June 20, 2018 at 10:30 a.m. ET in New York City.

Live webcasts of the UBS and Jefferies presentations will be available on the Company's website at www.argenx.com. Replays of the webcasts will be available for 90 days following the presentation.

About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  

www.argenx.com

For further information, please contact:

Joke Comijn, Corporate Communications & IR Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
[email protected]

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
[email protected]

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx's expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: argenx SE via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARGEN-X
10:31aSHIRE : argenx receives milestone payment from strategic collaboration with Shir..
AQ
07/17ARGEN X : argenx receives milestone payment from strategic collaboration with Sh..
GL
07/03ARGEN X : argenx receives second preclinical milestone payment under its develop..
AQ
06/29ARGEN X : argenx receives second preclinical milestone payment under its develop..
AQ
06/28ARGEN X : argenx receives second preclinical milestone payment under its develop..
GL
06/28ARGEN X : argenx receives second preclinical milestone payment under its develop..
AQ
06/25ARGEN X : argenx reports interim data from first cohort of Phase 2 proof-of-conc..
AQ
06/21ARGEN X : argenx reports interim data from first cohort of Phase 2 proof-of-conc..
AQ
06/20ARGEN X : argenx reports interim data from first cohort of Phase 2 proof-of-conc..
GL
06/18ARGEN X : argenx announces data from Phase 1 study of efgartigimod subcutaneous ..
AQ
More news
News from SeekingAlpha
07/09Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growin.. 
06/29INFLARX : Buy The Dip 
06/22YOUR DAILY PHARMA SCOOP : Reata Begins New Trial, CytoDyn Amends Protocol, Argen.. 
06/223 THINGS IN BIOTECH, JUNE 21 : Regeneron Sneaks Up In The Kidney Cancer Space 
06/20Argenx's efgartigimod shows encouraging action in mid-stage pemphigus vulgari.. 
Financials (€)
Sales 2018 27,9 M
EBIT 2018 -70,6 M
Net income 2018 -75,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 90,6x
Capi. / Sales 2019 52,8x
Capitalization 2 532 M
Chart ARGEN-X
Duration : Period :
arGEN-X Technical Analysis Chart | ARGX | NL0010832176 | 4-Traders
Technical analysis trends ARGEN-X
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 86,5 €
Spread / Average Target 9,9%
EPS Revisions
Managers
NameTitle
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Peter K. M. Verhaeghe Chairman
R. Keith Woods Chief Operating Officer
Eric Castaldi CFO & Principal Accounting Officer
Hans J. W. de Haard Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARGEN-X49.85%2 946
GILEAD SCIENCES7.76%100 380
VERTEX PHARMACEUTICALS20.93%46 529
REGENERON PHARMACEUTICALS-2.98%38 717
GENMAB8.36%10 693
NEUROCRINE BIOSCIENCES, INC.34.73%9 398